Login to view
Ola Akinboboye, MD, MPH, MBA, FACP, FACC, FASNC, FSCCT, FAHA, DABSM
Associate Professor of Clinical Medicine
Past President, Association of Black Cardiologists
Medical Director, Queens Heart Institute
Jan Basile, MD
Professor of Medicine
Seinsheimer Cardiovascular Health Program
Medical University of South Carolina
Ralph H. Johnson VA Medical Center
Phillip B. Duncan, MD
Heart Care for You, PC
Icilma V. Fergus, MD, FACC
President, Association of Black Cardiologists
Director, Cardiovascular Disparities and
Associate Professor of Medicine
Mount Sinai School of Medicine
New York, NY
Elizabeth Ofili, MD, MPH, FACC
Professor of Medicine (Cardiology)
Senior Associate Dean, Clinical Research
Director, Clinical Research Center
Morehouse School of Medicine
Founder and Chairman of the Board, AccuHealth Technologies, Inc.
Anekwe Onwuanyi, MD
Professor of Medicine
Chief of Cardiology
Morehouse School of Medicine
Medical Director, Heart Failure Program
Grady Health System
Laurence O. Watkins, MD, MPH, FACC
Director, Healthy Heart Center
Port St. Lucie, FL
Karol E. Watson, MD, PhD
Professor of Medicine/Cardiology
Co-director, UCLA Program in Preventive Cardiology
Director, UCLA Barbra Streisand Women’s Heart Health Program
Los Angeles, CA
Estimated Time To Complete CME Activity:
Welcome to the Association of Black Cardiologists, Inc. webcast that was recorded at NACE Emerging Challenges in Primary Care 2015 conference in Raleigh, NC. The topic of this webcast is Lipid Management and Cardiovascular Risk Reduction: The Evolving Treatment Paradigm.
After completing this program participants should be able to:
- Discuss the benefits of LDL-C lowering with pharmacologic therapies that improve cardiovascular outcomes
- Understand the role of alternative or additional therapies in conjunction with statins
- Identify the strengths and limitations of the 2013 ACC/AHA cholesterol guidelines and how to optimally implement the recommendations
- Recognize the potential role of emerging pharmacologic therapies to further lower LDL-C in those at high risk for cardiovascular disease
- Develop appropriate treatment strategies for special populations (women, elderly, ethnic minorities) that would benefit from lipid lowering therapy.
How To Obtain Your CME Certificate
- Register for the course at http://naceonline.com
- Complete and submit the post-test and evaluation.
- A minimum passing score of 60% must be earned on the post-test in order to complete the CME activity.
- Print your CME certificate.
Association of Black Cardiologists, Inc.
|Accreditation Designation Statement
The Association of Black Cardiologists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Association of Black Cardiologists is designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.
The Association of Black Cardiologists (ABC) requires faculty, planners, managers, staff and other individuals who are in a position to control the content of CME activities to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by ABC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content and appropriateness of patient care recommendations. Faculty disclosures are provided below.
Ola Akinboboye, MD, MPH, MBA, FACP, FACC, FASNC, FSCCT, FAHA, DABSM, Faculty Committee, serves as a speaker for Takeda Pharmaceuticals and Arbor Pharmaceuticals and is a grant writer for BMS.
Jan Basile, MD, Faculty Committee, receives grant/research support from The National Heart, Lung, and Blood Institute (Sprint). Dr. Basile serves as a consultant for Amgen, Arbor, Eli-Lilly, Forest Labs, Janssen, Lundbeck, Medtronic annd Novartis; and he participates on the speakers bureau for Arbor and Janssen.
Phillip B. Duncan, MD, Faculty Committee, is a consultant/speaker for Arbor Pharmaceuticals.
Icilma V. Fergus, MD, FACC, Faculty Committee, has no relationships to disclose.
Elizabeth Ofili, MD, MPH, Faculty Committee, receives grant/research support from the National Institutes of Health. Dr. Ofili serves as a consultant and/or on the advisory board for Bristol-Myers Squibb, Novartis, Arbor, Eli-Lilly, Merck & Co., Janssen Research and Development.
Anekwe Onwuanyi, MD, Faculty Committee, has no relationships to disclose.
Laurence O. Watkins, MD, MPH, FACC, Speaker and Faculty Committee, serves as a speaker/teacher for Arbor Pharmaceuticals and on the advisory committee for Boston Scientific.
Karol Watson, MD, PhD, Faculty Committee, receives serves as a consultant for Amgen, Astra Zeneca, Daiichi Sankyo, GSK, Merck and Quest.
Cassandra McCullough, Activity Planning Committee, has no relationships to disclose.
Walter Wolyniec, MSc., Activity Planning Committee, has no relationships to disclose.
Gregg Sherman, MD, Course Director, has no relationships to disclose.
Harvey C. Parker, Ph.D., Activity Planning Committee, has the following relationships to disclose: co-owner of Specialty Press, Inc. and Health Link Systems, Inc.
Michelle Frisch, MPH, Activity Planning Committee, has no relationships to disclose.
Alan Goodstat, LCSW, Activity Planning Committee, has no relationships to disclose.
Sheila Lucas, CWEP, Activity Planning Committee, has no relationships to disclose.
Cheryl C. Kay, Activity Planning Committee, has no relationships to disclose.
This activity is supported by an educational grant from sanofi-aventis U.S. and Regeneron Pharmaceuticals.